KB-1101

PVRIG-antibody

Background

Poliovirus receptor-related immunoglobulin domain-containing (PVRIG) has recently been identified as an immune checkpoint molecule with potential for therapeutic development. In humans, PVRIG is expressed on T cells (predominantly CD8+ T cells) and natural killer (NK) cells, but not on B cells, monocytes or neutrophils. PVRIG binds to a single ligand, poliovirus receptor-related 2 (PVRL2, also known as CD112 or Nectin-2), and exerts an inhibitory effect on cytotoxic lymphocyte activity, likely via an ITIM-like motif in its intracellular domain. PVRIG blocking antibodies significantly increased NK-cell cytotoxicity against breast cancer cell lines in vitro, and an effect was further enhanced when used in combination with TIGIT blocking antibodies.

Specifications

Catalog Number:
KB-1101
Cell Line Name:
PVRIG-antibody
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PVRIG
Species Reactivity:
Human
Application:
ELISA | FACS | Function assay
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS | Function assay

References

1.Zhu Y, Paniccia A, Schulick AC. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016; 213(2):167-176. 2.Whelan S, Ophir E, Kotturi MF. PVRIG and PVRL2 Are induced in cancer and Inhibit CD8(+) T-cell function. Cancer Immunol Res. 2019; 7(2):257-268. 3.Li M, Qiao D, Pu J, Wang W, Zhu W, Liu H.. Elevated Nectin-2 expression is involved in esophageal squamous cell carcinoma by promoting cell migration and invasion. Oncol Lett. 2018; 15(4):4731-4736.
Please enable JavaScript in your browser to complete this form.